Cargando…

Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm of advanced-stage non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The aim of this study was to evaluate the effectiveness and tolerance of ICIs in a real-world patient population and to investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shijia, Pease, Daniel F, Kulkarni, Amit A, Kumar, Manoj, Shanley, Ryan M, Xu, Beibei, Joshi, Shilvi P, Patel, Manish R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237437/ https://www.ncbi.nlm.nih.gov/pubmed/34248362 http://dx.doi.org/10.1177/11795549211004489

Ejemplares similares

Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study
por: Su, Ruopeng, et al.
Publicado: (2023)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration
por: Siempis, Thomas, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
por: Guardascione, Michela, et al.
Publicado: (2020)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia
por: Al Nuhait, Mohammed, et al.
Publicado: (2021)

Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
por: Tsai, Hong-Ming, et al.
Publicado: (2021)

Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis
por: Zou, Huimin, et al.
Publicado: (2022)

Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population()
por: Kuznicki, Michelle L., et al.
Publicado: (2020)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
por: Kim, Roger Y., et al.
Publicado: (2021)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer
por: Chan, John K., et al.
Publicado: (2023)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types
por: Kulkarni, Amit A, et al.
Publicado: (2020)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
por: Oya, Yuko, et al.
Publicado: (2020)

Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Takada, Shinya, et al.
Publicado: (2020)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
por: Singal, Amit G., et al.
Publicado: (2022)

Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System
por: La, Jennifer, et al.
Publicado: (2020)

Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy
por: Gupta, Vineet Govinda, et al.
Publicado: (2019)

Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
por: Hanna, Glenn J., et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
por: Gong, Xiaoling, et al.
Publicado: (2022)

Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy
por: Cone, Eugene B., et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review
por: Ma, Xiaoting, et al.
Publicado: (2021)

Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer
por: Takeuchi, Eiji, et al.
Publicado: (2022)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
por: Reed, George W., et al.
Publicado: (2019)

Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study
por: Leicher, Laura W., et al.
Publicado: (2016)

Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis
por: Shah, Bela J., et al.
Publicado: (2020)

A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
por: Kim, Jung Sun, et al.
Publicado: (2022)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021)

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis
por: Zhou, Chengjing, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor–Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
por: Wang, Li, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4j1r2a587l04otrl0d9hkfar8g